DYNOCARDIA, INC.

SBIR Phase II: Development of motion artifact correction systems for ViTrack: an accurate, continuous, and non-invasive blood pressure monitor

DYNOCARDIA, INC. is active in the biomedical eng and diagnostics space based in NEWTON CENTER, MA, founded in 2018.

Profile

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project is to meet the urgent need for a wearable blood pressure (BP) monitor for accurate and continuous BP measurements. The current standard for arm cuff-based BP assessments is unreliable and limited to single time-point BP estimates, but an individual’s BP fluctuates significantly over 24 hours. In US hospitals, 35 million patients are admitted annually for critical illness and/or undergo major surgeries that require BP monitoring. Inaccurate, single-point, cuff-based BP monitoring during surgery leads to unrecognized low BP and contributes to 14 million heart attacks and kidney failures annually. ViTrack is a wrist-wearable device that utilizes a proprietary optomechanical sensor array and computer vision to accurately and continuously measure radial artery BP without requiring external calibration. However, continuously measuring BP in clinical settings is challenging due to artifacts from patient movements. In NSF Phase 1, ViTrack's sensor array was used to develop an advanced computer vision technology for motion artifact correction. Other than the hospital market, the multi-billion dollar market segments for an accurate and continuous BP monitor include remote patient monitoring for 104 million Americans with high BP and the consumer wellness markets.

The objective

DYNOCARDIA, INC. is positioned in biomedical eng and diagnostics, a segment that rewards a clear, focused offering.

The company is recorded as being based in NEWTON CENTER, MA.

Its current recorded stage is SBIR Phase II.

The company reports a headcount in the 1-10 range.

Public records show total funding of about $1,K.

Website: dynocardia.care